🇺🇸 FDA
Patent

US 10947312

Human antibodies to GFRα3 and methods of making thereof

granted A61KA61K2039/505A61K39/001103

Quick answer

US patent 10947312 (Human antibodies to GFRα3 and methods of making thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K2039/505, A61K39/001103, A61K39/39533, A61K39/39541